Showing 4041-4050 of 4164 results for "".
- Kala Pharmaceuticals Completes of Enrollment of STRIDE 3 Trial for Eysuvis for Dry Eye Diseasehttps://modernod.com/news/kala-pharmaceuticals-announces-completion-of-enrollment-of-stride-3-trial-for-eysuvis-for-dry-eye-disease/2477232/Kala Pharmaceuticals announced that it has completed enrollment in its STRIDE 3 (STRIDE – Short Term Relief In Dry Eye) phase 3 clinical trial for KPI-121 0.25%, its product candidate for the short-term treatment of dry eye disease. If approved, Kala plans to commercialize KPI-121 0.25% under the
- New Chair, Members Named to Eversight Board of Directorshttps://modernod.com/news/new-chair-members-named-to-eversight-board-of-directors/2477217/Eversight announced that two new members and a new chair have been named to its Board of Directors, effective Jan. 1, 2020. Joining the Eversight Board of Directors are Carolyn Welsh, Vice President & Chief Clinical Officer, NJ Sharing Network; and Mahmoud N. Ghazzi, MD, PhD, MPH, an e
- Tarsus Pharmaceuticals Raises $60 Million for Demodex Blepharitis Drug Trialhttps://modernod.com/news/tarsus-pharmaceuticals-raises-60-million-for-demodex-blepharitis-drug-trial/2477213/Tarsus Pharmaceuticals announced the completion of $60 million in Series B financing. Tarsus will use the funds to initiate a phase 2b/3 trial in the United States of their lead product TP-03 for Demodex blepharitis and fuel phase 1 and 2 development of other clinical programs. An estimate
- Eyevensys Closes $30M Series B Financinghttps://modernod.com/news/eyevensys-closes-30m-series-b-financing/2477210/Eyevensys announced that it has completed a $30 million Series B financing. The company will use the funds to continue the development of its clinical lead candidate EYS606 for the treatment of chronic noninfectious uveitis (NIU), including the launch of its Electro Study. This phase 2 trial, to
- Nicox’s NCX 4251 Meets Primary Endpoint in Phase 2 Blepharitis Trial and Shows Promising Efficacy in Dry Eye Diseasehttps://modernod.com/news/nicoxs-ncx-4251-meets-primary-endpoint-in-phase-2-blepharitis-trial-and-shows-promising-efficacy-in-dry-eye-disease/2477187/Nicox SA announced that NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals, has met the primary objective of its U.S. multicenter, dose escalating, first-in-human, phase 2 clinical trial (referred to as ‘Danube’) evaluating the safety and tolerability of NCX 4
- Staar Surgical Announces Strategic Alliance Agreement with California Center for Refractive Surgery (CCRS)https://modernod.com/news/staar-surgical-announces-strategic-alliance-agreement-with-california-center-for-refractive-surgery-ccrs/2477178/Staar Surgical announced it has entered into a strategic alliance with the California Center for Refractive Surgery (CCRS), a Los Angeles based eye care group with locations in Hancock Park and Sherman Oaks. “Our new multi-clinic alliance with CCRS and its founder Dr. Paul Lee is represent
- Envision Announces Dates, Calls for Submissions for 2020 Conferenceshttps://modernod.com/news/envision-announces-dates-calls-for-submissions-for-2020-conferences/2477082/Envision announced that it is now accepting submissions for clinical education and research presentations for its two annual conferences in 2020: Envision Conference West, April 3-4, UT Health San Antonio Department of Occupational Therapy in San Antonio, Texas; and Envision Conference East, Augu
- Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil in Phase 2 Study Conducted in Japanhttps://modernod.com/news/aerie-pharmaceuticals-announces-positive-topline-results-for-netarsudil-in-phase-2-study-conducted-in-japan/2477069/Aerie Pharmaceuticals reported positive topline results for the company’s phase 2 clinical trial evaluating netarsudil ophthalmic solution in Japanese patients. Netarsudil is a Rho kinase (ROCK) inhibitor specifically designed to increase outflow of aqueous humor through the trabecular meshwork,
- Omeros Announces Publication of Study Results on the Impact of Omidria on Opioid Use and Painhttps://modernod.com/news/omeros-announces-publication-of-study-results-on-the-impact-of-omidria-on-opioid-use-and-pain/2477067/Omeros announced that results of a prospective, controlled study showing that Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3% reduces use of the opioid fentanyl during cataract surgery while also reducing surgical pain were published in the peer-reviewed journal Clinical Oph
- CooperVision’s ECP Viewpoints Begins Educational Series Based on Company and Company-Sponsored Researchhttps://modernod.com/news/coopervisions-ecp-viewpoints-begins-educational-series-based-on-company-and-company-sponsored-research/2477042/Eye care professionals attending Academy 2019 have access to hundreds of scientific papers and posters that showcase the latest advances in optometry research. But digesting and translating this information for the benefit of their own practices can be a challenge. To further support its clinical